Who
Sanjay Shukla
President and CEO
Company insider
Files Form 4 as: President and CEO, aTyr Pharma.
In numbers
- Trades disclosed
- 51
- Buys
- 12
- Sells
- 3
- Bought
- $286K
- Sold
- $16K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Mar 2016
- Last trade
- 4 Feb 2026
- Last filed
- 4 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Sold | $3,6553,745 at $0.976 | filing |
| 4 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Sold | $3,6703,745 at $0.98 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —10,375 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,375 at $0.00 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,375 at $0.00 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —10,375 | filing |
| 9 Jan 2026filed 9 Jan 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500,000 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500,000 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,375 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —10,375 | filing |
| 8 Jan 2025filed 10 Jan 2025 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 31 May 2024filed 3 Jun 2024 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $36K20,000 at $1.81 | filing |
| 5 Feb 2024filed 6 Feb 2024 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,375 at $0.00 | filing |
| 5 Feb 2024filed 6 Feb 2024 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —10,375 | filing |
| 5 Jan 2024filed 9 Jan 2024 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 12 Dec 2023filed 12 Dec 2023 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $14K12,000 at $1.18 | filing |
| 11 Dec 2023filed 12 Dec 2023 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $3,5103,000 at $1.17 | filing |
| 13 Nov 2023filed 13 Nov 2023 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $15K13,578 at $1.11 | filing |
| 10 Nov 2023filed 13 Nov 2023 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $1,6211,422 at $1.14 | filing |
| 28 Jul 2023filed 1 Aug 2023 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $30K15,000 at $2.01 | filing |
News
No headline names them, or the companies they trade most, lately.